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Aim of the work: The present work aimed to explore the possible anti-arthritic effects of taurine
in comparison with diclofenac.
Materials and methods: Rats were allocated into ﬁve groups (n= 10). The normal and control
groups received normal saline. The remaining three groups were treated with diclofenac (2 mg/kg),
taurine (5 mg/kg), or taurine (50 mg/kg), respectively. Drugs were i.p. injected for 26 successive days
starting from the onset of adjuvant induction. Arthritis was induced by s.c. injection of 0.4 ml of
Freund’s complete adjuvant (FCA) into the subplantar region of the right hind paws of rats in
all groups except the normal one. Paw volume was measured before and at different time intervals
after adjuvant inoculation. After the last measurement, blood samples were collected and were used
for estimation of serum levels of lipid peroxides, nitrite, total antioxidants, tumor necrosis factor-
alpha, and interleukin-1beta as well as lactate dehydrogenase activity. Histopathological examina-
tion of knee tissues of all rats was also performed.
Results: Injection of FCA induced marked arthritis manifested by paw edema during the 26-day
experiment period. Treatment with diclofenac or taurine (50 mg/kg) markedly inhibited adjuvant
arthritis as well as its associated biochemical and histological changes. Taurine (5 mg/kg) did not
affect FCA-induced paw edema but it attenuated some of the induced biochemical changes.040447; fax: +20 224073411.
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Rheumatoid arthritis (RA) is a chronic autoimmune inﬂam-
matory joint disorder which often leads to disability and can
considerably affect the patient’s quality of life [1]. The patho-
genesis of RA is predominantly associated with the formation
of reactive oxygen species (ROS), pro-inﬂammatory cytokines,
and other inﬂammatory mediators as prostaglandins at the site
of inﬂammation [1,2].
Conventional therapies in RA as steroids and non-steroidal
anti-inﬂammatory drugs (NSAIDs) help in controlling symp-
toms of arthritis, nevertheless their effects on disease progres-
sion as well as their adverse effectsmake them unsatisfactory [3].
Taurine is a semi-essential non-protein amino acid that is
present abundantly in several mammalian tissues as well as
pro-inﬂammatory cells as polymorphonuclear leukocytes [4].
Taurine’s protective effects have been demonstrated in some
inﬂammatory conditions [5–7]. One of the proposed protective
mechanisms of taurine is its reaction with hypochlorous acid,
produced via myeloperoxidase pathway, to produce taurine
chloramines, a powerful anti-inﬂammatory agent [8].
The present work was designed to investigate the possible
anti-arthritic effect of taurine, in an experimental model of
arthritis, and to compare such effects with diclofenac, a known
anti-inﬂammatory agent. In an attempt to understand the possi-
ble underlying mechanism(s) of taurine effects, assessment of
certain biochemical parameters related to arthritis, as tumor
necrosis factor-alpha (TNF-a), interleukin-1beta (IL-1b), nitric
oxide metabolites, total antioxidant capacity, lactate dehydro-
genase (LDH) activity, and formation of thiobarbituric acid
reactive substances (TBARS), were also done in serum. In addi-
tion, histopathological examination of joint tissue was
performed.
2. Materials and methods
2.1. Animals
Male Wistar rats of 120–150 g body weight were used in the
current investigation. They were obtained from the National
Cancer Institute (Cairo, Egypt) and were kept in the animal
house of the faculty of Pharmacy, Cairo University at a temper-
ature of 25 ± 1 C, humidity of 60 ± 5% and natural lighting
conditions. Rats were fed on a standard pellet chow (El-Nasr
Chemical Company, Cairo, Egypt) and allowed free access to
water. The study was carried out according to the international
guidelines of the Care and Use of Laboratory Animals and ap-
proved by the Ethics Committee for Animal Experimentation
at the Faculty of Pharmacy, Cairo University.
2.2. Chemicals
Taurine and Freund’s complete adjuvant (FCA) were pur-
chased from Sigma Chemical Company, USA. Diclofenac so-
dium was purchased from Novartis Pharma, Egypt. Taurineand diclofenac were dissolved in normal saline prior to admin-
istration. Kits for determination of TNF-a and IL-1b were
purchased from Quantikine, R&D Systems, USA. Kit for
determination of LDH was obtained from Stanbio, USA. Kits
for determination of total antioxidants, nitrite, and lipid per-
oxides were purchased from Biodiagnostic, Egypt. All other
used chemicals were of analytical grade.
2.3. Experimental design
Rats were randomly allocated into ﬁve groups each consisting
of 10 animals. Three groups were treated with diclofenac
sodium (2 mg/kg), taurine (5 mg/kg), or taurine (50 mg/kg),
respectively. Drugs were dissolved in normal saline and were
i.p. injected to rats. The other two groups were i.p. injected
with normal saline; one served as normal group and the other
served as control group. Polyarthritis was induced by s.c. injec-
tion of 0.4 ml of FCA [9] into the subplantar region of the right
hind paws of rats of all groups except the normal one. Drugs
were administered once daily for 26 consecutive days starting
from the onset of adjuvant inoculation. To assess the time
course of adjuvant-induced edema, paw volume was measured
before and after 4, 7, 11, 14, 19, 21, and 26 days of adjuvant
inoculation by volume displacement method using a water ple-
thysmometer (Ugo Basile, Italy). The last measurement of paw
volume was performed 1 h after administration of the last dose
of the test agents. Then, blood samples were collected via the
retro-orbital venous plexus of each rat and were used for
serum separation and estimation of LDH activity as well as
TBARS, nitrite, total antioxidants, TNF-a and IL-1b
concentrations.
2.4. Biochemical measurements
Serum LDH activity was estimated kinetically and expressed
as U/ml. Serum TBARS and nitrite were determined colori-
metrically using commercially available kits; their concentra-
tions were expressed as nmol/ml. Serum TNF-a and IL-1b
concentrations were determined by sandwich enzyme linked
immunosorbent assay (ELISA) technique and their concentra-
tions were expressed as pg/ml. Total antioxidants were deter-
mined colorimetrically using commercial kits and expressed
as lmol/ml. The assay reﬂects the integrative potential of all
enzymatic and non-enzymatic antioxidants present in serum.
2.5. Histopathological examination
The limbs of all animals were dissected and placed in a 0.4 M
EDTA, 0.3 N NaOH, solution, which was changed every
3 days, for 4–5 weeks to achieve decalciﬁcation (end-point
determined by physical assessment). Each specimen was
embedded in parafﬁn wax and sectioned in the sagittal plane
starting from the medial margin. Serial sections in knee joints
with a thickness of 6 lm were taken. The sections were stained
with hematoxylin and eosin for histopathological
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Adobe Photoshop version 8.0.
Statistics. Values were presented as means ± S.E. One-way
analysis of variance (ANOVA) followed by Least Signiﬁcant
Difference (LSD) post hoc test was used to determine the dif-
ference between the groups in terms of all studied parameters
using SPSS software (version 11.0). Results were considered
statistically signiﬁcant when p< 0.05.
3. Results
FCA injected into the hind paw of rats induced marked edema
during the 26 days experiment period. In the control group, the
percentage of edema volume to initial paw volume (% edema)
maximally recorded 77% after the 19th day from adjuvant
inoculation (Fig. 1). Diclofenac (2 mg/kg/day) signiﬁcantly
inhibited FCA-induced paw edema at all the studied time
intervals when compared to the control group. Treatment with
taurine (5 mg/kg/day) showed no signiﬁcant effect on paw ede-
ma as compared to the control group. On the other hand, tau-
rine (50 mg/kg/day) afforded signiﬁcant reduction in % edema
at days 4, 7, 11, 19, 21, and 26 (Fig. 1).
Serum LDH activity of the normal group recorded
0.16 ± 0.01 U/ml. FCA markedly elevated such activity to
0.41 ± 0.04 U/ml in the control group. Treatment with diclofe-
nac, the low and high doses of taurine signiﬁcantly reduced
FCA-induced activation of serum LDH recording 68.7%,
48.5%, and 27.2% of the control value, respectively (Fig. 2A).
In addition, the obtained results revealed that taurine by either
dose lowered serum LDH activity signiﬁcantly as compared to
diclofenac treatment in dose-dependent manner.Figure 1 Time course effects of diclofenac (2 mg/kg) and taurine
(5, 50 mg/kg) on Freund’s complete adjuvant-induced hind paw
edema. Drugs were administered i.p. once daily for 26 consecutive
days starting from the onset of adjuvant inoculation. Control
group received saline daily. Paw volume was measured before and
after 4, 7, 11, 14, 19, 21, and 26 days of adjuvant inoculation by
volume displacement method. The last measurement of paw
volume was performed 1 h after the last dose administration. Each
point represents the mean of nine experiments ± S.E. *p< 0.05
vs. control, @p< 0.05 vs. diclofenac, #p< 0.05 vs. taurine (5).Normal serumTBARS level was 9.12 ± 0.93 nmol/ml. FCA
increased lipid peroxidation as manifested by 1.5-fold increase
in serum TBARS level recording 13.83 ± 1.15 nmol/ml in the
control group. Daily treatment with diclofenac, taurine (5 mg/
kg), and taurine (50 mg/kg) produced signiﬁcant reductions in
FCA-induced lipid peroxidation recording 71.7%, 42.5%, and
46.8% of the control value, respectively (Fig. 2B). Also, when
compared to diclofenac, serum TBARS levels of taurine-treated
groups were signiﬁcantly lower than that of diclofenac-treated
group.
Normal level of serum nitrites was 8.84 ± 1.04 nmol/ml.
FCA signiﬁcantly elevated nitrites level to 12.95 ± 1.19 nmol/
ml in the control group. Treatment with diclofenac and taurine
(50 mg/kg) signiﬁcantly reduced such level to 61.3% and 47.4%
of the control value, respectively (Fig. 2C). On the contrary, the
low dose of taurine did not produce any signiﬁcant change in
this parameter.
Serum total antioxidant capacity was not signiﬁcantly
changed by adjuvant arthritis or by treatment with any of
the test agents (Fig. 2D).
Serum TNF-a level of the normal group recorded
15.61 ± 2.01 pg/ml. FCA signiﬁcantly increased this level to
25.34 ± 3.33 pg/ml in the control group. Treatment with dic-
lofenac, the low and high doses of taurine signiﬁcantly de-
creased TNF-a to 56%, 63%, and 52% of the control value,
respectively (Fig. 2E).
Serum level of IL-1b was 65.26 ± 6.86 pg/ml in the normal
group. FCA markedly increased IL-1b level to 97.58 ± 7.80
pg/ml in the control group. Diclofenac produced a signiﬁcant
reduction in this level recording 73% of control value. On the
contrary, treatment with taurine by either dose failed to reduce
IL-1b level (Fig. 2F).
On examining the histological sections, a healthy articular
surface was observed in the normal control animals with a
smooth, uninterrupted surface and an even distribution of
chondrocytes often arranged in columns (Fig. 3A–C); whereas,
in arthritic control animals joint surfaces were abraded and
contained ﬁbrotic tissue (Fig. 3D–F). The present results re-
vealed that using diclofenac (Fig. 4A–C) and taurine in the
large dose level (Fig. 4G–I) reduced the damaging effect of
adjuvant arthritis especially on the articular surfaces. Lesser
protective effects were shown by the small dose of taurine
(Fig. 4D–F).4. Discussion
In the current study, FCA resulted in marked paw edema dur-
ing the 26-day experiment period. Prophylactic daily treatment
with diclofenac markedly inhibited the adjuvant-induced
arthritis at all studied time intervals.
Adjuvant-induced arthritis is commonly used in evaluating
the anti-arthritic potential of new drugs [10]. The inﬂamma-
tory response in RA is complicated and involves immunologic
reactions, complement activation, release of various mediators
and chemotactic factors as well as leukocytic inﬁltration of
joints [11,12].
Diclofenac is one of the widely used NSAIDs in treatment
of RA and other inﬂammatory conditions [13]. Suppression of
paw edema by diclofenac can be largely attributed to inhibi-
tion of PGs-mediated vasodilation and exudation [14] as well
as its antioxidant and free radical scavenging properties
Figure 2 Effects of diclofenac (2 mg/kg) and taurine (5, 50 mg/kg) on serum levels of: (A) LDH activity, (B) TBARS, (C) nitrite, (D)
total antioxidants, (E) TNF-a, and (F) IL-1b of rats subjected to Freund’s complete adjuvant-induced polyarthritis. Polyarthritis was
induced in all groups except the normal one. Drugs (saline for normal and control groups) were administered i.p. once daily for 26
consecutive days starting from the onset of adjuvant inoculation. Blood samples were collected 2 h after the last dose administration. Each
bar represents the mean of 5–10 experiments ± S.E.M. shown by vertical line. *p< 0.05 vs. normal, @p< 0.05 vs. control, #p< 0.05 vs.
diclofenac, p< 0.05 vs. taurine (5).
134 H.F. Zaki et al.[15,16]. Moreover, diclofenac was shown to attenuate certain
factors known to aggravate joint destruction in rheumatic dis-
eases as myeloperoxidase produced by activated neutrophils
[17] and release of lysosomal enzymes [18].
In the present study, administration of taurine in the large
dose level (50 mg/kg) signiﬁcantly reduced paw edema induced
in rats by FCA. The effects of taurine were even comparable to
that of diclofenac, one of the standard anti-rheumatic drugs.
The present results support those of other investigators,
about the anti-inﬂammatory effect of taurine in models of
acute inﬂammation in rats [19,20].
It was found that taurine chloramine, formed in vivo by
activated neutrophils, inhibits secretion of some pro-inﬂamma-tory cytokines which are crucial in pathogenesis of RA as
interleukin-6 (IL-6) and interleukin-8 (IL-8) [21]. Moreover,
taurine chloramine was found to inhibit IL-1b-induced pro-
duction of cyclo-oxygease-2 (COX-2) and generation of pros-
taglandins (PGE2) by RA synoviocytes [22].
In the present study, induction of adjuvant arthritis was
coupled by marked increases in serum TBARS level and
LDH activity. Moreover, prophylactic treatment with diclofe-
nac or taurine in both dose levels reduced lipid peroxidation as
evidenced by decreased formation of TBARS and reduced
LDH activity, as compared to the control arthritic group.
The effects of taurine were even signiﬁcantly better than those
of diclofenac.
Figure 3 Histopathological changes in knee joint of arthritic rats. (A) Shows a normal structure of a joint where the articular surfaces
are covered with a smooth layer of hyaline cartilage (arrow). The synovial space is of normal width (star). (B and C) Show the soft tissue of
the limb composed mainly of collagen ﬁbers (arrow) in which bundles of skeletal muscle ﬁbers and fat cells are embedded (arrow head).
(D) Shows section in control arthritic group revealing degradation of the articular surface where it becomes adherent and continuous with
the connective tissue around (arrow). The connective tissue itself is highly inﬁltrated with cellular inﬁltrates (star). (E) Shows also
cartilaginous degradation (arrow head) and signs of inﬂammation in the soft tissue in the form of highly cellular inﬁltrates and vacuolar
degeneration (arrow). (F) Higher magniﬁcation of the site of inﬂammation that shows that the cellular inﬁltrates are mainly composed of
neutrophils (arrow head) denoting acute inﬂammation. (H&E · 40, 1000).
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events that contribute to the pathophysiology of arthritis
[23,24]. Several studies have documented an imbalance in the
body’s reduction/oxidation homeostasis in arthritic subjects
and experimental animals [23,25,26]. A frequently used marker
of lipid peroxidation is malondialdehyde (MDA) assessed as
an adduct with thiobarbituric acid. Studies have shown in-
creased plasma level of MDA in patients and animals with
RA [27,28]. Lipid peroxidation produces marked alteration
in molecular organization of membrane lipid resulting in in-
creased membrane permeability and leakage of cytoplasmic
markers as LDH into circulation [29] which could account
for the rise in LDH activity observed in the control arthritic
group.
The observed protective effects of diclofenac on serum
TBARS level and LDH activity could be attributed to its doc-
umented antioxidant and free radical scavenging properties
[15,16]. Concerning taurine, it was shown to reduce lipid per-
oxidation and restore depleted glutathione and antioxidant
stores in a model of endotoxin-induced lung inﬂammation
[6]. In a study performed by Das et al. [30], taurine supplemen-
tation was shown to reduce acetaminophen-induced increase in
serum LDH, NO, TNF-a and lipid peroxide products. The
antioxidant effects of taurine were demonstrated in several
other studies both in vivo [31] and in vitro [32]. The antioxidant
effect of taurine is unique as it can attenuate lipid peroxidation
and antioxidant defenses depletion in models of oxidative
stress despite lacking a readily oxidizable functionality [4,33].
The observed lack of change in serum total antioxidants le-
vel by the experimentally-induced arthritis or treatments in the
present study is strange considering that oxidative stress was
evident from the elevated TBARS level and LDH activity. To-tal antioxidants assay reﬂects the total capacity of different
antioxidants present in serum including enzymes as superoxide
dismutase, glutathione peroxidase and catalase as well as non-
enzymes as reduced glutathione, vitamin C, uric acid and oth-
ers. During oxidative stress, individual antioxidants may either
be depleted or increased as a compensatory mechanism.
Hence, perhaps RA led to an increase of one or more of these
members and depletion of others leading to a net result of un-
changed total antioxidants level. Further experiments may be
needed to clarify this point.
Pretreatment of rats with diclofenac, in the present study,
reduced arthritis-induced elevation in serum levels of nitrite,
TNF-a and IL-1b. Diclofenac treatment was shown to reduce
elevated serum levels of NO and TNF-a in arthritic rats [34].
In RA, the synovium is intensively inﬁltrated by macro-
phages which are the major source of TNF-a, IL-1b and induc-
ible nitric oxide synthase (iNOS) mediated NO generation
during immune response [35]. Both TNF-a and IL-1b play a
key role in the induction and perpetuation of immunological
inﬂammation by activating T cells and macrophages and by
up-regulating other pro-inﬂammatory cytokines and endothe-
lial adhesion molecules [36,37]. Consequently, the levels of
both cytokines are expected to decrease with diclofenac treat-
ment owing to reduction of inﬂammation and lipid peroxida-
tion which are major inducers of cytokines production by
macrophages [38].
Prophylactic treatment of arthritic rats with taurine re-
duced elevated serum levels of nitrite and TNF-a whereas no
effect was observed on the level of IL-1b. The present ﬁndings
are supported by previous reports that taurine chloramine
inhibits production of NO, TNF-a, and other pro-inﬂamma-
tory mediators by activated cells from various tissues [21,39].
Figure 4 Histopathological changes in knee joint of arthritic rats treated with diclofenac or different dose levels of taurine. (A) Section in
a synovial joint from an animal treated with diclofenac, where repair of articular surfaces is markedly observed except for small areas at
one side (arrow head) and remaining ﬁbrous tissue invading the joint (arrow). (B) Shows the soft tissue around the joint where edema,
vacuolar degeneration and cellular inﬁltrates are markedly reduced (arrow) by diclofenac. (C) Higher magniﬁcation of the site of
inﬂammation showing that the cellular inﬁltrate is being made up of neutrophils (arrow head) and lymphocytes (arrow). (D) Shows a
section in a synovial joint and the soft tissue around it from a rat treated with taurine in a dose of 5 mg/kg, where irregularities in articular
surfaces and invasion of connective tissue is still present (wavy arrow). Also the cellular inﬁltrate (arrow) and the edema (double-ended
arrow) in soft tissues are still observed. (E) Vacuolar degeneration (v) is still seen. (F) Shows the components of the cellular inﬁltrate that is
made up from segmented neutrophils of variable sizes with some lymphocytes. (G and H) Show sections in a synovial joint and the soft
tissue around it from a rat treated with taurine in a dose of 50 mg/kg, where there is normalization of the articular surfaces except for a
very small area at one side (arrow head) with reduction in signs of inﬂammation of the soft tissue (arrow). (I) Section from the same group
showing the cellular inﬁltrate which is composed of neutrophils (arrow head) and some localized lymphocytes (arrow) in addition, large
areas of vacuolar degeneration (v) exist. (H&E · 40, 1000).
136 H.F. Zaki et al.Moreover, Marcinkiewicz et al. [40] demonstrated similar pro-
tective effects by taurolidine, a derivative of taurine, in various
experimental models of synovitis.
Production of pro-inﬂammatory cytokines is regulated at
the genetic level through the activity of certain transcription
factors as nuclear factor-kappa (NF-jB) which regulates
expression of iNOS, TNF-a and other pro-inﬂammatory medi-
ators [41]. Taurine chloramine was shown to inhibit the expres-
sion of iNOS and TNF-a by inhibiting NF-jB signal
transduction pathway [42].
Histological examination of knee tissues of control arthritic
rats revealed inﬂammation and degradation of the articular
surface accompanied by marked cellular inﬁltration of connec-
tive tissues coupled with vacuolar degeneration of cartilages.
Diclofenac and taurine in the large dose level led to marked re-
pair of articular surfaces and reduction of soft tissue edema,
vacuolar degeneration and cellular inﬁltration. Lesser protec-
tive effects were observed by the small dose of taurine. Theseﬁndings correlate with the measured biochemical parameters
and the results of paw edema.
In conclusion, taurine attenuated most of the biochemical
and pathophysiological aspects of RA. Such effects could be
explained by the observed effects of taurine on oxidative stress
biomarkers, production of NO and pro-inﬂammatory cyto-
kines as TNF-a. The effects of taurine were comparable to that
of diclofenac which is an important ﬁnding to consider owing
to the documented adverse effects of NSAIDS and other RA
conventional therapies.Acknowledgement
The authors are very grateful to Dr. Nermeen M. Shafﬁe,
Department of Pathology, Medical Division, National Re-
search Center, Giza, Egypt, for examining and interpreting his-
topathological aspects of this study.
Taurine: A promising agent of therapeutic potential in experimentally-induced arthritis 137References
[1] Firestein GS. Evolving concepts of rheumatoid arthritis. Nature
2003;423:356–61.
[2] Firestein GS. Etiology and pathogenesis of rheumatoid arthritis.
In: Kelly WN, Ruddy S, Harris ED, Sledge CB, editors. Textbook
of rheumatology. Philadelphia: Saunders; 1996. p. 851–97.
[3] Scheiman JM. The impact of non-steroidal anti-inﬂammatory
drug-induced gastropathy. Am J Manag Care 2001;7:10–4.
[4] Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant
action of taurine, hypotaurine and their metabolic precursors.
Biochem J 1988;256:251–5.
[5] Son MW, Ko JI, Doh HM, Kim WB, Park TS, Shim MJ, et al.
Protective effect of taurine on TNBS-induced inﬂammatory bowel
disease in rats. Arch Pharm Res 1998;21(5):531–6.
[6] Bhavsar TM, Patel SN, Lau-Cam CA. Protective action of
taurine, given as a pretreatment or as a posttreatment, against
endotoxin-induced acute lung inﬂammation in hamsters. J Biomed
Sci 2010;17(Suppl 1):S19–31.
[7] Nakajima Y, Osuka K, Seki Y, Gupta RC, Hara M, Takayasu M,
et al. Taurine reduces inﬂammatory responses after spinal cord
injury. J Neurotrauma 2010;27(2):403–10.
[8] Verdrengh M, Tarkowski A. Inhibition of septic arthritis by local
administration of taurine chloramines, a product of activated
neutrophils. J Rheumatol 2005;32(8):1513–7.
[9] Barbier A, Navarro J, Breliere JC, Roncucci R. Biochemical and
clinical changes in rats with developing adjuvant arthritis. Agents
Actions 1984;15:103–5.
[10] Weichmann BM. Rat adjuvant arthritis. A model of chronic
inﬂammation. In: Weichmann BM, editor. Pharmacological
methods in the control of inﬂammation. New York: Alan R. Liss
Inc.; 1989. p. 363–80.
[11] Swingle KF. Evaluation of anti-inﬂammatory activity. In: Scher-
rer RA, Whitehouse MW, editors. Anti-inﬂammatory agents:
Chemistry and pharmacology. New York: Academic Press; 1974.
p. 34–122.
[12] Rotelli AE, Guardia T, Juarez AO, de la Rocha NE, Pelzer LE.
Comparative study of ﬂavonoids in experimental models of
inﬂammation. Pharmacol Res 2003;48:601–6.
[13] Hickey EJ, Raie RR, Reid VE, Gross SM, Ray SD. Diclofenac
induced in vivo nephrotoxicity may involve oxidative stress-
mediated massive genomic DNA fragmentation and apoptotic cell
death. Free Radic Biol Med 2001;31:139–52.
[14] Ku EC, Wasvary JM, Cash WD. Diclofenac sodium (GP45840,
Voltaren), a potent inhibitor of prostaglandin synthetase. Bio-
chem Pharmacol 1975;24:641–3.
[15] Bell AL, Adamson H, Kirk F, McCaigue MD, Rotman H.
Diclofenac inhibits monocytes superoxide production ex vivo in
rheumatoid arthritis. Rheumatol Int 1991;11:27–30.
[16] Curcelli EC, Muller SS, Novelli Filho JL. Beneﬁcial effects of
diclofenac therapy on serum lipids, oxidized low-density lipopro-
tein and antioxidant defenses in rats. Life Sci 2008;82:892–8.
[17] Zuurbier KW, Bakkenist AR, Fokkens RH, Nibbering NM,
Wever R, Muijers AO. Interaction of myeloperoxidase with
diclofenac. Inhibition of chlorinating activity of myeloperoxidase
by diclofenac and oxidation of diclofenac to dihydroxyazobenzene
by myeloperoxidase. Biochem Pharmacol 1990;40:1801–8.
[18] Menasse´ R, Hedwall PR, Kraetz J, Pericin C, Riechester L,
Sallmann A, et al. Pharmacological properties of diclofenac
sodium and its metabolites. Scand J Rheumatol 1978;22:5–16.
[19] Bhattacharya SK, Sarkar MK. Effect of some centrally admin-
istered putative amino acid neurotransmitters on carrageenan-
induced paw oedema in rats. J Pharm Pharmacol
1986;38(2):144–6.
[20] Stapleton PP, Mahon TM, Nowlan P, Bloomﬁeld FJ. Effects of
in-vivo administration of taurine and HEPES on the inﬂamma-
tory response in rats. J Pharm Pharmacol 1994;46(9):745–50.[21] Kontny E, Grabowska A, Kowalczewski J, Kurowska M, Janicka
I, Marcinkiewicz J, et al. Taurine chloramine inhibition of cell
proliferation and cytokine production by rheumatoid arthritis
ﬁbroblast-like synoviocytes. Arthritis Rheum 1999;42:2552–60.
[22] Kontny E, Rudnicka W, Kowalczewski J, Marcinkiewicz J,
Maslinski W. Selective inhibition of cyclooxygenase 2-generated
prostaglandin E2 synthesis in rheumatoid arthritis synoviocytes by
taurine chloramines. Arthritis Rheum 2003;48:1551–5.
[23] Hitchon CA, El-Gabalawy HS. Oxidation in rheumatoid arthritis.
Arthritis Res Ther 2004;6:265–78.
[24] Kunsch C, Sikorski JA, Sundell CL. Oxidative stress and the use
of antioxidants for the treatment of rheumatoid arthritis. Curr
Med Chem Immunol Endocr Metab Agents 2005;5:249–58.
[25] Bauerova K, Bezek A. Role of reactive oxygen and nitrogen
species in etiopathogenesis of rheumatoid arthritis. Gen Physiol
Biophys 1999;18:15–20.
[26] Bohanec GP, Logar D, Tomsic M, Rozman B, Dolzan V. Genetic
polymorphisms modifying oxidative stress are associated with
disease activity in rheumatoid arthritis patients. Dis Markers
2009;26:41–8.
[27] Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D, et al.
Assessment of paraoxonase 1 activity and malondialdehyde levels
in patients with rheumatoid arthritis. Clin Biochem 2005;38:951–5.
[28] He YH, Zhou J, Wang YS, Xiao C, Tong Y, Tang JC, et al. Anti-
inﬂammatory and anti-oxidative effects of cherries on Freund’s
adjuvant-induced arthritis in rats. Scand J Rheumatol
2006;35:356–8.
[29] Mason RP, Walter MF, Mason PE. Effect of oxidative stress on
membrane structure: small-angle X-ray diffraction analysis. Free
Radic Biol Med 1997;23:419–25.
[30] Das J, Ghosh J, Manna P, Sil PC. Acetaminophen induced acute
liver failure via oxidative stress and JNK activation: protective
role of taurine by the suppression of cytochrome P450 2E1. Free
Radic Res 2010;44(3):340–55.
[31] Li CY, Deng YL, Sun BH. Taurine protected kidney from
oxidative injury through mitochondrial-linked pathway in a rat
model of nephrolithiasis. Urol Res 2009;37:211–20.
[32] Pan C, Giraldo GS, Prentice H, Wu JY. Taurine protection of PC
12 cells against endoplasmic reticulum stress induced by oxidative
stress. J Biomed Sci 2010;17(Suppl 1):S1–S17.
[33] Hanna J, Chahine R, Aftimos G, Nader M, Mounayar A, Esseily
F, et al. Protective effect of taurine against free radicals damage
in the rat myocardium. Exp Toxicol Pathol 2004;56:189–94.
[34] El-Ghazaly MA, El-Naby DH, Khayyal MT. The inﬂuence of
irradiation on the potential chondroprotective effect of aqueous
extract of propolis in rats. Int J Radiat Biol 2011;87(3):254–62.
[35] Ma Y, Pope RM. The role of macrophages in rheumatoid
arthritis. Curr Pharm Des 2005;11:569–80.
[36] Beutler B, Cerami A. The biology of cachectin/TNF-a primary
mediator of the host response. Ann Rev Immunol 1989;7:625–55.
[37] Molloy RG, Mannick JA, Rodrick ML. Cytokines, sepsis and
immunomodulation. Br J Surg 1993;80:289–97.
[38] Choy EH, Panayi GS. Cytokine pathways and joint inﬂammation
in rheumatoid arthritis. N Engl J Med 2001;344:907–16.
[39] Kim C, Park E, Quinn MR, Schuller-Levis G. The production of
superoxide anion and nitric oxide by cultured murine leukocytes
and the accumulation of TNF-a in the conditioned media is inhib-
ited by taurine chloramine. Immunopharmacology 1996;34:89–95.
[40] Marcinkiewicz J, Gluszko P, Kontny R, Kwas´ny-Krochin B,
Bobek M, Wierzchowski W, et al. Clin Exp Rheumatol
2007;25(2):211–8.
[41] Baldwin Jr AS. The NF-jB and IjB proteins: new discoveries and
insights. Annu Rev Immunol 1996;14:649–83.
[42] Barua M, Liu Y, Quinn MR. Taurine chloramine inhibits
inducible nitric oxide synthase and TNF-a gene expression in
activated alveolar macrophages: Decreased NF-jB activation and
IjB kinase activity. J Immunol 2001;167:2275–81.
